Freenome Inc FRNM

$12.77 -0.33 (-2.52%)

Valuation

Market cap
1,505,332,000
Revenue TTM
$30,409,000
Net income TTM
$840,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
610,600
Avg volume
869,152
Day's range
$12.48 – $13.13
Shares out
107,447,000
Stochastic %K
35%
Beta
0.44
Analysts
Strong Sell
Price target
$18.00

Price

Company profile

Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung,...

Show more

Freenome, Inc. operates as a biotechnology company in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops blood-based tests, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.

Industry
Diagnostics & Research
Sector
Healthcare
Phone
(650) 446-6630
Website
https://www.freenome.com
Address
3300 Marina Boulevard, Brisbane, United States

Latest news

Stocktwits

notreload_ai Oct 20, 6:43 PM
$FRNM launched SimpleScreen Lung, a blood test for smokers ages 50-80 not currently screened. It detected 85% of lung cancers and almost always correctly says no cancer if negative. https://notreload.xyz/wall-street-live-tuesday-october-20/
0 replies
thingkfast Oct 12, 9:28 PM
$FRNM what’s the reason for the dump? Manipulation?
1 replies
AlertsAndNews Oct 11, 10:21 PM
$FRNM Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 "today announced the company will present late-breaking data on an updated version of its SimpleScreen™ CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville."
0 replies
STACKD0E Oct 11, 9:01 PM
$FRNM
0 replies
Rayvio_News_Filter Oct 11, 5:01 PM
$FRNM 🏥 Freenome, Inc. announced late-breaking validation data for its updated SimpleScreen CRC blood-based screening test at ACG 2026, showing significant improvement across all subtypes of advanced precancerous lesions and 80.4% sensitivity at 90% specificity for colorectal cancer. Selected from hundreds of headlines
0 replies
Laynester Sep 21, 2:25 PM
$SVIA $FRNM $UMC $HITI $FFIV Added on to all these this morning. Set an alert/stop. Good skills and future returns to all.
0 replies
STRelativeStrength Sep 18, 2:20 PM
$FRNM undiscovered breakout with 73 watchers
0 replies
STRelativeStrength Sep 7, 2:05 PM
$FRNM undiscovered breakout with 76 watchers
0 replies